Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | PDE7A | Q13946 | 7/20 | 0.51 |
| ▸ | SETD2 | Q9BYW2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12124282 | 0.80 | NPC1 (0.71) | NPC1RAB9AALDH1A1HPGDKMT2A | |
| SCHEMBL12124281 | 0.78 | RAB9A (0.88) | NPC1RAB9AALDH1A1HPGDMEN1 | |
| SCHEMBL3767054 | 0.75 | KDM1A (0.43) | PDE7ASETD2ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL20478065 | 0.75 | KDM1A (0.43) | PDE7ASETD2ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL20478066 | 0.75 | KDM1A (0.43) | PDE7ASETD2ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL2723003 | 0.75 | KDM1A (0.43) | PDE7ASETD2ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL2696025 | 0.75 | KDM1A (0.43) | PDE7ASETD2ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL2696030 | 0.75 | KDM1A (0.43) | PDE7ASETD2ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL12124266 | 0.72 | RAB9A (0.77) | NPC1RAB9AALDH1A1HPGDMEN1 | |
| SCHEMBL12124255 | 0.72 | RAB9A (0.77) | NPC1RAB9AALDH1A1HPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8134013-B2 | Amide compound and thrombopoietin receptor activator | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-03-13 | — | — | US | disclosed |
| US-8134013-B2 | Amide compound and thrombopoietin receptor activator | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2012-03-13 | — | — | US | disclosed |
| US-20090131659-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| US-20090131659-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131659-A1 | AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR | TEK, PTAFR, MPL | NPC1 3107/4885RAB9A 2458/4885PDE7A 2037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.